20-valent pneumococcal conjugate vaccine
Trade name: Prevnar 20
VaccineapprovedBreakthrough Therapy FDA
Approved
Jun 8, 2021
Clinical trial activity
52 trials · 17 clinical orgs · 1 marketing orgs
Phase 1
13
Phase 2
39
Phase 3
28
Phase 4
4
Earliest trial started Dec 12, 2018 (NCT03760146)
Timeline
Indications
Approved for
Studied for
- alpha 1-Antitrypsin · Phase 4
- Anemia, Sickle Cell · Phase 3
- Chickenpox · Phase 3
- COVID-19 · Phase 4
- Deficiency Diseases · Phase 4
- Healthy Volunteers · Phase 3
- HIV Infections · Phase 4
- Lymphoma · Phase 4
- Pneumococcal Infections · Phase 4
- Pneumococcal Vaccines · Phase 2
- Pneumonia · Phase 3
- Pneumonia, Bacterial · Phase 1
- Pulmonary Disease, Chronic Obstructive · Phase 4
- Respiratory Syncytial Virus Infections · Phase 3
- Respiratory Syncytial Virus Vaccines · Phase 3
- Streptococcus pneumoniae · Phase 1
- Vaccines · Phase 1
Mechanism of action
- Streptococcus pneumoniaeImmunity, active
Streptococcus pneumoniae immunity, active
Approval history
- approvedBreakthroughJun 8, 2021
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07300267 | Phase 1 | Jan 21, 2026 | Merck |
| NCT07284654 | Phase 3 | Dec 1, 2025 | Vaxcyte, Inc. |
| NCT07247188 | Phase 3 | Nov 24, 2025 | Sanofi |
| NCT07168915 | Phase 1 | Oct 8, 2025 | Merck |
| NCT07135427 | Phase 4 | Sep 3, 2025 | Alpha-1 Foundation, University of Alabama, Birmingham |
| NCT07160244 | Phase 3 | Aug 25, 2025 | Pfizer |
| NCT07105722 | Phase 1 | Aug 12, 2025 | GlaxoSmithKline |
| NCT07086677 | Phase 1 | Jul 22, 2025 | Pfizer |
| NCT07019909 | Phase 1 | Jul 6, 2025 | Pfizer |
| NCT06986239 | Phase 1 | Jul 1, 2025 | LiteVax BV |
| NCT07023081 | Phase 1 | Jun 15, 2025 | Pfizer |
| NCT07059182 | Phase 1 | Jun 11, 2025 | Serum Life Science Europe GmbH |
| NCT06855160 | Phase 3 | Apr 17, 2025 | GlaxoSmithKline |
| NCT06806137 | Phase 3 | Mar 5, 2025 | GlaxoSmithKline |
| NCT06838000 | Phase 3 | Feb 28, 2025 | Sanofi, Sanofi-Aventis |
| NCT06824181 | Phase 3 | Feb 27, 2025 | Sanofi |
| NCT06824194 | Phase 3 | Feb 18, 2025 | Sanofi |
| NCT06790290 | Phase 2 | Jan 27, 2025 | Inventprise Inc. |
| NCT06740630 | Phase 3 | Dec 17, 2024 | GlaxoSmithKline |
| NCT06736041 | Phase 3 | Dec 16, 2024 | Sanofi-Aventis |
Showing 20 of 52 trials
Page 1 / 3
Organizations
Research & Development (17)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 21 | 21 | 3 | 2018 |
| GlaxoSmithKline | For profit | 6 | 6 | 2 | 2023 |
| Vaxcyte, Inc. | For profit | 6 | 6 | 2 | 2022 |
| Merck | For profit | 4 | 4 | 2 | 2022 |
| Sanofi | For profit | 4 | 3 | 1 | 2025 |
| Inventprise Inc. | For profit | 3 | 3 | 1 | 2022 |
| Sanofi-Aventis | For profit | 3 | 3 | 1 | 2024 |
| Canadian Center for Vaccinology | Academic/Hospital | 2 | 0 | 1 | 2022 |
| PATH | Academic/Hospital | 2 | 0 | 1 | 2022 |
| University of British Columbia | Academic/Hospital | 2 | 0 | 1 | 2022 |
| Alpha-1 Foundation | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Hennepin Healthcare | Academic/Hospital | 1 | 1 | 1 | 2024 |
| LiteVax BV | For profit | 1 | 1 | 1 | 2025 |
| Medical University of Vienna | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Serum Life Science Europe GmbH | For profit | 1 | 1 | 1 | 2025 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2023 |
17 organizations
Page 1 / 1